Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $252 from $283 and keeps a Buy rating on the shares. Q1 EBITDA upside “layers another proof-point that THC has the capacity to manage in an uncertain environment,” the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Shines In Q1 2026 Earnings Call
- Morning Movers: Check Point, Meta dip following earnings
- Tenet Healthcare reports Q1 adjusted EPS $4.82, consensus $4.17
- Tenet Healthcare backs FY26 adjusted EBITDA view $4.485B-$4.785B
- Tenet Healthcare sees FY26 adjusted EPS $16.38-$18.68, consensus $17.19